🇺🇸 FDA
Patent

US 7575742

Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 7575742 (Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/7052